<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04049799</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00000166</org_study_id>
    <secondary_id>R01DA047867</secondary_id>
    <nct_id>NCT04049799</nct_id>
  </id_info>
  <brief_title>Maternal Opioid Treatment: Human Experimental Research - Data Yield Appropriate Decisions</brief_title>
  <acronym>MOTHER DYAD</acronym>
  <official_title>Medically-supervised Withdrawal vs. Agonist Maintenance in the Treatment of Pregnant Women With Opioid Use Disorder: Maternal, Fetal, and Neonatal Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Vermont</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Vermont</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare medically-supervised withdrawal (MSW, 'detoxification') to opioid
      agonist treatment (OAT, 'maintenance') with buprenorphine for pregnant women with opioid use
      disorder in terms of maternal, fetal, and neonatal outcomes. Outcomes will be assessed during
      pregnancy, at birth and for 12 months postpartum. This study has the potential to impact
      health service policy and practices in terms of the treatment options of pregnant women with
      opioid use disorder.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Some inclusion/exclusion criteria are purposely omitted at this time to preserve scientific
      integrity. They will be included after the trial is complete.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 8, 2019</start_date>
  <completion_date type="Anticipated">October 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of mothers who discontinued 1st treatment choice prior to delivery</measure>
    <time_frame>Antepartum period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of mothers engaged in treatment at delivery</measure>
    <time_frame>Antepartum period</time_frame>
    <description>Behavior health treatment or medical treatment in past 21 days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of mothers with illicit substance use at delivery</measure>
    <time_frame>At delivery</time_frame>
    <description>Positive vs. negative for any illicit substance in the urine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of mother-child dyads with delivery complications</measure>
    <time_frame>At delivery</time_frame>
    <description>Yes vs. no code for the presence or absence of delivery complications such as uterine rupture, placental abruption, low birth weight, chorioamnionitis, and meconium staining</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of neonates receiving medication treatment for neonatal abstinence syndrome (NAS)</measure>
    <time_frame>At hospital discharge, an average of 10 days after delivery</time_frame>
    <description>Yes vs. no</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total average amount of medication given to treat NAS</measure>
    <time_frame>At hospital discharge, an average of 10 days after delivery</time_frame>
    <description>Morphine Equivalent Dose in mg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total average length of neonatal hospital stay</measure>
    <time_frame>At hospital discharge, an average of 10 days after delivery</time_frame>
    <description>Days</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Opioid-use Disorder</condition>
  <condition>Opioid Withdrawal</condition>
  <condition>Neonatal Abstinence Syndrome</condition>
  <condition>Neonatal Opioid Withdrawal Syndrome</condition>
  <arm_group>
    <arm_group_label>Medically-supervised withdrawal (MSW)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Opioid agonist treatment (OAT)</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Medically-supervised withdrawal</intervention_name>
    <description>6-8 day withdrawal with buprenorphine/naloxone</description>
    <arm_group_label>Medically-supervised withdrawal (MSW)</arm_group_label>
    <other_name>Detoxification</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Opioid agonist treatment</intervention_name>
    <description>Induction and maintenance with buprenorphine/naloxone</description>
    <arm_group_label>Opioid agonist treatment (OAT)</arm_group_label>
    <other_name>Maintenance</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Comprehensive clinical care</intervention_name>
    <description>Obstetrical visits, counseling, case management, psychiatry services, and urine drug screening</description>
    <arm_group_label>Medically-supervised withdrawal (MSW)</arm_group_label>
    <arm_group_label>Opioid agonist treatment (OAT)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant women seeking treatment for opioid use disorder
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be ages 18 to 41, inclusive

          -  Have a single fetus pregnancy between 6-30 weeks estimated gestational age

          -  Willing to participate in the study

        Exclusion Criteria:

          -  Non-English speaking
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>41 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sarah H Heil, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Vermont</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sarah H Heil, PhD</last_name>
    <phone>802-656-8712</phone>
    <email>sarah.heil@uvm.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>UNC Chapel Hill Horizons</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hendree Jones, PhD</last_name>
      <phone>919-966-9803</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Vermont</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Heil, PhD</last_name>
      <phone>802-656-9615</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lori Keyser-Marcus, PhD</last_name>
      <phone>804-827-1727</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>July 23, 2019</study_first_submitted>
  <study_first_submitted_qc>August 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 8, 2019</study_first_posted>
  <last_update_submitted>March 18, 2020</last_update_submitted>
  <last_update_submitted_qc>March 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Vermont</investigator_affiliation>
    <investigator_full_name>Sarah Heil</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neonatal Abstinence Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Substance Withdrawal Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Analgesics, Opioid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

